Investor Relations

Company Profile

Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. Our most advanced product candidate is RMC-4630, a clinical-stage drug candidate that potently and selectively inhibits SHP2, a central node in the RAS signaling pathway. In collaboration with our partner, Sanofi, we are evaluating RMC-4630 in a multi-cohort Phase 1/2 clinical program for a range of tumor types featuring specific oncogenic mutations. Additionally, we are developing a portfolio of mutant-selective RAS inhibitors that we believe are the first potent, selective, cell-active inhibitors of the active, GTP-bound form of RAS, or RAS(ON). Our pipeline also includes inhibitors of other frontier oncology targets within the RAS and mTOR pathways. These include SOS1 and 4EBP1/mTORC1, with a development candidate for the latter, RMC-5552, currently advancing into IND-enabling studies.

Stock Quote




Data Provided by Refinitiv. Minimum 15 minutes delayed.

Search Investor Relations